Quality of life assessment in chronic viral hepatitis

Tatyana Polukchi 1 2 * , Zulfiya Zhankalova 3, Gulzhan Abuova 2, Akhmedova Muborakhon 4
More Detail
1 Department of Gastroenterology, S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
2 Department of Infectious Diseases and Dermatovenerology, South Kazakhstan Medical Academy, Shymkent, Kazakhstan
3 Department of General Medical Practice, S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
4 Department of Infectious and Children Infectious Diseases, Tashkent Medical Academy, Tashkent, Uzbekistan
* Corresponding Author
J CLIN MED KAZ, Volume 19, Issue 3, pp. 19-23. https://doi.org/10.23950/jcmk/12149
Download Full Text (PDF)


Chronic viral hepatitis has a significant impact on morbidity, quality of life and mortality and is characterized by a growing economic and social burden in the context of disability of the population and an increase in life expectancy. Chronic viral hepatitis can significantly worsen health-related quality of life indicators (HRQoL), which are a reflection of the influence of the disease and therapy on the physical and emotional components of the patient's health, especially in patients with progressive liver disease and/or active viral activity. To assess the quality of life related to health, you can use general tools and tools for specific diseases. Common tools available in the scientific literature include the Short Form 36 questionnaire (SF-36) and the Euroqol five-point questionnaire (EQ-5D). However, since general instruments cannot always detect the subtle effects of a particular condition on the quality of life, the use of special instruments is of great value, due to their ability to clinically characterize the quality of life in patients with chronic viral hepatitis. The use of recently developed special tools for assessing the quality of life will greatly assist in the verification of preventive and therapeutic interventions in this area. One of the priorities of any measures for the prevention and treatment of chronic viral hepatitis is to improve the quality of life in this category of patients.


Polukchi T, Zhankalova Z, Abuova G, Muborakhon A. Quality of life assessment in chronic viral hepatitis. J CLIN MED KAZ. 2022;19(3):19-23. https://doi.org/10.23950/jcmk/12149


  • Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis: Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention. Infect Dis Clin North Am. 2019;33(4):1045-1062. https://doi.org/10.1016/j.idc.2019.08.004
  • Conde I, Vinaixa C, Berenguer M. Hepatitis C-related cirrhosis. Current status. Med Clin (Barc). 2017;148(2):78-85. English, Spanish. https://doi.org/10.1016/j.medcli.2016.09.019
  • Bruggmann P et al. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil. BMC Infect Dis. 2020;20(1):114. https://doi.org/10.1186/s12879-020-4809-2
  • Basit H, Tyagi I, Koirala J. Hepatitis C. 2021 Nov 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 28613647.
  • Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardí R, Sauleda S et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18(6):434-42. https://doi.org/10.1111/j.1365-2893.2010.01324.x
  • Rizzetto M. Hepatitis D virus: introduction and epidemiology. Cold Spring Harb Perspect Med. 2015;5:1–9. https://doi.org/10.1101/cshperspect.a021576
  • Komas N.P., Ghosh S., Abdou-Chekaraou M., Pradat P., Al Hawajri N., Manirakiza A. Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. PLoS Negl Trop Dis. 2018;12:1–18. https://doi.org/10.1371/journal.pntd.0006377
  • Pawełczyk A. Konsekwencje pozawątrobowe zakażenia wirusem zapalenia wątroby typu C (HCV) [Consequences of extrahepatic manifestations of hepatitis C viral infection (HCV)]. Postepy Hig Med Dosw (Online). 2016;70:349-59. Polish. https://doi.org/10.5604/17322693.1199988
  • Monaco S, Mariotto S, Ferrari S, Calabrese M, Zanusso G, Gajofatto A, Sansonno D, Dammacco F. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. World J Gastroenterol. 2015;21(42):11974-83. https://doi.org/10.3748/wjg.v21.i42.11974
  • Fagundes RN, Ferreira LEVVC, Pace FHL. Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free. PLoS One. 2020;15(8):e0237005. https://doi.org/10.1371/journal.pone.0237005
  • Fotos NV, Elefsiniotis I, Patelarou A, Giakoumidakis K, Patelarou E, Kouros A, Brokalaki H. Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis: A Single-Center Cross-Sectional Study With Pair-Matched Healthy Controls. Gastroenterol Nurs. 2018;41(3):206-218. https://doi.org/10.1097/SGA.0000000000000339
  • Yeoh SW, Holmes ACN, Saling MM, Everall IP, Nicoll AJ. Depression, fatigue and neurocognitive deficits in chronic hepatitis C. Hepatol Int. 2018;12(4):294-304. https://doi.org/10.1007/s12072-018-9879-5
  • Saeed YA, Phoon A, Bielecki JM, Mitsakakis N, Bremner KE, Abrahamyan L, Pechlivanoglou P, Feld JJ, Krahn M, Wong WWL. A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. Value Health. 2020;23(1):127-137. https://doi.org/10.1016/j.jval.2019.07.005
  • Adinolfi LE, Nevola R, Rinaldi L, Romano C, Giordano M. Chronic Hepatitis C Virus Infection and Depression. Clin Liver Dis. 2017;21(3):517-534. https://doi.org/10.1016/j.cld.2017.03.007
  • Więdłocha M, Marcinowicz P, Sokalla D, Stańczykiewicz B. The neuropsychiatric aspect of the HCV infection. Adv Clin Exp Med. 2017;26(1):167-175. https://doi.org/10.17219/acem/37787
  • Vu TTM, Le TV, Dang AK, Nguyen LH, Nguyen BC, Tran BX, Latkin CA, Ho CSH, Ho RCM. Socioeconomic Vulnerability to Depressive Symptoms in Patients with Chronic Hepatitis B. Int J Environ Res Public Health. 2019;16(2):255. https://doi.org/10.3390/ijerph16020255
  • Zhang Q, Zhong C, Cai S, Yu T, Xu X, Yin J. Risk Factors Associated With Quality of Life in Patients With Hepatitis B Virus Related Cirrhosis. Front Psychol. 2022;12:770415. https://doi.org/10.3389/fpsyg.2021.770415
  • Dirks M, Haag K, Pflugrad H, Tryc AB, Schuppner R, Wedemeyer H, Potthoff A, Tillmann HL, Sandorski K, Worthmann H, Ding X, Weissenborn K. Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. J Viral Hepat. 2019;26(4):422-431. https://doi.org/10.1111/jvh.12979
  • Dirks M, Pflugrad H, Haag K, Tillmann HL, Wedemeyer H, Arvanitis D, Hecker H, Tountopoulou A, Goldbecker A, Worthmann H, Weissenborn K. Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?! J Viral Hepat. 2017;24(7):541-550. https://doi.org/10.1111/jvh.12674
  • Bonnemain CL, Cochand L, Portmann A, Béguelin C. Nouveaux aspects de la prise en charge de l’hépatite D [Recent advances in managing hepatitis D]. Rev Med Suisse. 2019;15(666):1802-1806. https://doi.org/10.53738/REVMED.2019.15.666.1802
  • Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol. 2020;73(3):533-539. https://doi.org/10.1016/j.jhep.2020.02.030
  • Buti M, Stepanova M, Palom A, Riveiro-Barciela M, Nader F, Roade L, Esteban R, Younossi Z. Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. JHEP Rep. 2021;3(3):100280. https://doi.org/10.1016/j.jhepr.2021.100280
  • Shah NM, Malhotra AM, Kaltsakas G. Sleep disorder in patients with chronic liver disease: a narrative review. J Thorac Dis. 2020;12(Suppl 2):S248-S260. https://doi.org/10.21037/jtd-cus-2020-012
  • Jang ES, Kim YS, Kim KA, Lee YJ, Chung WJ, Kim IH, Lee BS, Jeong SH. Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D. Gut Liver. 2018;12(4):440-448. https://doi.org/10.5009/gnl17322
  • Gonzalez HC, Gordon SC. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life? Gastroenterol Clin North Am. 2020;49(2):301-314. https://doi.org/10.1016/j.gtc.2020.01.007
  • Goñi Esarte S, Juanbeltz R, Martínez-Baz I, Castilla J, San Miguel R, Herrero JI, Zozaya JM. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enferm Dig. 2019;111(6):445-452. https://doi.org/10.17235/reed.2019.6063/2018
  • Juanbeltz R, Castilla J, Martínez-Baz I, O'Leary A, Sarobe M, San Miguel R. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Qual Life Res. 2019;28(6):1477-1484. https://doi.org/10.1007/s11136-019-02111-1
  • Beaudart C, Biver E, Bruyère O, Cooper C, Al-Daghri N, Reginster JY, Rizzoli R. Quality of life assessment in musculo-skeletal health. Aging Clin Exp Res. 2018;30(5):413-418. https://doi.org/10.1007/s40520-017-0794-8
  • Syddall HE, Martin HJ, Harwood RH, Cooper C, Aihie Sayer A. The SF-36: a simple, effective measure of mobility-disability for epidemiological studies. J Nutr Health Aging. 2009;13(1):57-62. https://doi.org/10.1007/s12603-009-0010-4
  • Younossi ZM, Golabi P, Henry L. A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. J Clin Gastroenterol. 2019;53(5):331-341. https://doi.org/10.1097/MCG.0000000000001179
  • Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337-43. https://doi.org/10.3109/07853890109002087
  • Xue X, Cai S, Ou H, Zheng C, Wu X. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence. 2017;11:85-93. https://doi.org/10.2147/PPA.S127139
  • Siqueira FM, Ferreira VL, Borba HHL, Pontarolo R. Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies. Rev Inst Med Trop Sao Paulo. 2018;60:e72. https://doi.org/10.1590/S1678-9946201860072
  • Ohlendorf V, Schäfer A, Christensen S, Heyne R, Naumann U, Link R, Herold C, Schiffelholz W, Günther R, Cornberg M, Serfert Y, Maasoumy B, Wedemeyer H, Kraus MR. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J Viral Hepat. 2021;28(8):1206-1218. https://doi.org/10.1111/jvh.13546
  • Juanbeltz R, Martínez-Baz I, San Miguel R, Goñi-Esarte S, Cabasés JM, Castilla J. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS One. 2018;13(10):e0205277. https://doi.org/10.1371/journal.pone.0205277
  • Saeed S, Moodie EEM, Strumpf E, Gill J, Wong A, Cooper C, Walmsley S, Hull M, Martel-Laferriere V, Klein MB; Canadian Co-Infection Cohort Study Investigators. Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. J Viral Hepat. 2018;25(12):1507-1514. https://doi.org/10.1111/jvh.12985
  • Tanaka A, Kikuchi K, Miura R, Miura K, Mikami M, Aiso M, Takamori Y, Takikawa H. Validation of the Japanese version of the Chronic Liver Disease Questionnaire for the assessment of health-related quality of life in patients with chronic viral hepatitis. Hepatol Res. 2016;46(3):E45-50. https://doi.org/10.1111/hepr.12524
  • Younossi ZM, Stepanova M, Younossi I, Racila A. Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV. J Viral Hepat. 2021;28(3):484-492. https://doi.org/10.1111/jvh.13451
  • Stepanova M, Younossi I, Racila A, Younossi ZM. Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). Value Health. 2018;21(5):612-621. https://doi.org/10.1016/j.jval.2017.10.005
  • Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79. https://doi.org/10.1186/1477-7525-1-79
  • Godara SK, Thappa DM, Pottakkatt B, Hamide A, Barath J, Munisamy M, Chiramel MJ. Cutaneous manifestations in disorders of hepatobiliary system. Indian Dermatol Online J. 2017;8(1):9-15. https://doi.org/10.4103/2229-5178.198760